Bronstein, Gewirtz & Grossman LLC Urges F5, Inc. Investors to Act: Class Action Filed Alleging Investor Harm — Neutral
FFIV GlobeNewsWire — January 21, 2026New class action for F5, Inc. (FFIV) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/17/2026.
Figure Technology Solutions Announces Community Approved Update to Provenance Blockchain Foundation Structure — Neutral
FIGR GlobeNewsWire — January 21, 2026Figure announces a community-approved update to the Provenance Blockchain Foundation structure, taking responsibility for executing community directives.
These Analysts Revise Their Forecasts On D.R. Horton After Q1 Results — Positive
DHI Benzinga — January 21, 2026D.R. Horton, Inc. (NYSE: DHI) reported upbeat earnings for its fiscal 2026 first quarter on Tuesday.
Oklo Stock Upgraded to Buy. Meta Nuclear Deal Is a ‘Meaningful Step Forward. — Positive
META OKLO Barrons — January 21, 2026Oklo's agreement with Meta Platforms to power its data centers is ‘one of a few firm, binding partnerships today,' says BofA Securities.
Enphase Energy, Inc. looks interesting, driven by a rare combination of high short interest, significant free cash flow during a sector slowdown, and unusually low valuations. High gross profit margins and hefty cash levels are hard to ignore. Three key catalysts—new product launches, a potential short squeeze, and rising oil/gas prices—could drive a +70% to +100% return over 12 months.
NVTS vs. ADI: Which Semiconductor Stock Should You Buy Right Now? — Neutral
ADI NVTS Zacks Investment Research — January 21, 2026Analog Devices' AI-driven data center momentum and earnings visibility give it an edge over Navitas Semiconductor amid near-term revenue uncertainty.
Service Corporation International: Visible Demand, Solid Pricing Power, And Moat — Positive
SCI Seeking Alpha — January 21, 2026Service Corporation International earns a buy rating due to visible demographic-driven demand, strong pricing power, and durable cemetery-based moat. SCI benefits from a $16.8B preneed contract backlog, providing high revenue visibility and margin expansion potential as volumes grow. The cemetery segment's real estate scarcity and integrated funeral-cemetery model grant SCI structural advantages and pricing power over fragmented competitors.
DeFi Development Corp.: Solana's Institutional Backing A Key Tailwind — Positive
DFDV Seeking Alpha — January 21, 2026DeFi Development Corp. is rated bullish, driven by surging institutional adoption of real-world asset tokenization and Solana's growing credibility. DFDV's Solana holdings exceed 2 million tokens, positioning it to benefit from rapid tokenization growth and high staking rewards, with SOL offering ~10% APY. GENIUS Act-driven regulatory clarity has catalyzed DFDV's revenue, up 313% YoY to $7.53 million TTM, with FY2026 consensus revenue estimated at $18.7 million (+70% YoY).
SLM INVESTOR ALERT: Berger Montague Advises SLM Corporation a/k/a Sallie Mae (SLM) Investors of a February 17, 2026 Deadline — Neutral
SLM Newsfile Corp — January 21, 2026Philadelphia, Pennsylvania--(Newsfile Corp. - January 21, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against SLM Corporation a/k/a Sallie Mae (NASDAQ: SLM) ("Sallie Mae" or the "Company") on behalf of investors who purchased or otherwise acquired Sallie Mae securities during the period of July 25, 2025 through August 14, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Sallie Mae securities during the Class Period may, no later than February 17, 2026, seek to be appointed as a lead plaintiff representative of the class.
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission — Positive
IBRX Zacks Investment Research — January 21, 2026IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February — Positive
CAPR Zacks Investment Research — January 21, 2026CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.
ROYAL CARIBBEAN GROUP NAMED TO THE FORTUNE WORLD'S MOST ADMIRED COMPANIES™ 2026 LIST FOR THE FIRST TIME — Neutral
RCL PRNewsWire — January 21, 2026Recognition reflects global reputation for innovation, leadership and culture MIAMI, Jan. 21, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) has been named to the Fortune World's Most Admired Companies 2026 list, marking a defining moment in the company's evolution into a global vacation leader. The annual ranking, compiled by Fortune® in partnership with Korn Ferry, surveys executives, directors, and industry analysts to evaluate companies across nine key reputation attributes including innovation, quality of management, products and services, social responsibility, and long-term investment value.
PetroTal Corp. (TAL:CA) Q4 2025 Guidance Call Transcript — Neutral
PTALF TAL Seeking Alpha — January 21, 2026PetroTal Corp. (TAL:CA) Q4 2025 Guidance Call Transcript
New Jersey Resources Board of Directors Declares Quarterly Dividend — Neutral
NJR Business Wire — January 21, 2026WALL, N.J.--(BUSINESS WIRE)--The board of directors (the “Board”) of New Jersey Resources Corporation (NYSE: NJR) unanimously declared a quarterly dividend on its common stock of $0.475 per share. The dividend will be payable on April 1, 2026, to shareowners of record as of March 11, 2026. NJR has paid quarterly dividends continuously since its inception in 1952, and has raised the dividend every year for the last 30 years. About New Jersey Resources New Jersey Resources (NYSE: NJR) is a Fortun.
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know — Positive
CRVS Seeking Alpha — January 21, 2026Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund pivotal Phase 2/3 trials, with durability of response as the next critical catalyst.
'Buy Now, Cry Later'? Kerrisdale Says Affirm Is A Subprime Time Bomb — Negative
AFRM Benzinga — January 21, 2026Affirm Holdings Inc (NASDAQ: AFRM) stock has been ripping higher, returning investors about 30% over the past year. Analysts have price targets suggesting at least 30-40% upside, and retail optimism is building — but Kerrisdale Capital says the entire rally is built on a familiar and dangerous illusion.
Can Vertiv's International Expansion Drive More Upside in the Stock? — Positive
VRT Zacks Investment Research — January 21, 2026VRT's overseas momentum accelerates as AI demand lifts sales, expands backlog to $9.5B, and supports continued double-digit organic growth.
Murphy USA remains a soft "Buy" despite recent underperformance and near-term financial weakness. MUSA's growth strategy centers on expanding larger format stores and leveraging geographic advantages for above-market fuel volume growth. Management targets $1.3 billion EBITDA by 2028, with substantial share buybacks potentially boosting annualized upside to 13%–22%.
Sandisk, a major provider of NAND flash memory, experienced a notable increase in its stock driven by strong trading volume. This surge was linked to a sector-wide pursuit of data storage assets, propelled by relentless AI-driven demand from hyperscalers.
D.R. Horton Stock Tests Support Following Earnings Report — Neutral
DHI MarketBeat — January 21, 2026Shares of homebuilder D.R. Horton Inc. NYSE: DHI are down about 1% in mid-day trading after the company reported its earnings for the first quarter of its 2026 fiscal year.